Clinical trials: Sjögren's Syndrome
Primary Sjögren's Syndrome
A Study to Evaluate the Efficacy and Safety of ICP-488 in Participants With Primary Sjögren's Syndrome
This is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical study to evaluate the efficacy and safety of ICP-488 in participants with primary Sjögren's syndrome (pSjS).
- Trial name
- NCT07727486
- Testing
- ICP-488 Tablets
- Where
- 22 sites in China
- Volunteers
- 240 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Dry Eye With Sjögren's Syndrome
An Extension Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome
The purpose of this study is to evaluate of the long-term safety and efficacy of KCT-0809 in dry eye patients with Sjögren's syndrome.
- Trial name
- NCT02503176
- Testing
- KCT-0809 ophthalmic solution
- Where
- Japan
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Healthy Volunteers, Sjögren's Syndrome
A Study to Evaluate the Effects of ASP5502 in Healthy Adults and Adults With Primary Sjögren's Syndrome
Primary Sjögren's syndrome (pSS) is a condition when the body's immune system attacks glands that produce fluids, such as the tear and saliva glands. This leads to dry eyes and a dry mouth.
- Trial name
- NCT06544642
- Testing
- ASP5502
- Where
- United States
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Global Development, Inc.
Autoimmune Diseases
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Proof of Mechanism of GSK2618960 in Primary Sjögren's Syndrome (pSS)
This study aims to evaluate the safety, tolerability and PK of repeat dose administration of GSK2618960 in the treatment of pSS.
- Trial name
- NCT03239600
- Testing
- GSK2618960 2 mg/kg, Methotrexate
- Where
- United Kingdom
- Sponsor
- GlaxoSmithKline
Primary Sjögren's Syndrome (pSS)
CM336 for Active Sjogren's Syndrome Study
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of CM336 in adult participants with active primary Sjogren's Syndrome.
- Trial name
- NCT07642843
- Testing
- CM336
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Keymed Biosciences Co.Ltd
Sjögren's Syndrome
A Study of LY3090106 in Participants With Sjögren's Syndrome (SS)
The main purpose of this study is to learn more about the safety and side effects of the study drug known as LY3090106 in participants with Sjögren's Syndrome (SS).
- Trial name
- NCT02614716
- Testing
- LY3090106
- Where
- 7 sites in United States, Bulgaria and 2 more
- Volunteers
- 32 people
- Sponsor
- Eli Lilly and Company
Stevens-Johnson Syndrome, Graft Versus Host Disease in Eye
Evaluation of Tangible Boost for Patients With Stevens Johnson Syndrome, Sjogren's Syndrome, and Graft Vs Host Disease
The goal of this research is to determine if the Tangible Boost system adequately replenishes the Hydra-PEG coating on the surface of a rigid contact lens.
- Conditions
- Stevens-Johnson Syndrome, Graft Versus Host Disease in Eye, Sjogren's Syndrome, Dry Eye
- Trial name
- NCT04313725
- Testing
- Tangible Boost
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Tangible Science
Primary Sjogrens Disease
A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome
The main purpose of the proposed study is to evaluate the efficacy of efgartigimod PH20 SC in patients with moderate-to-severe Primary Sjögren's Disease (pSjD).
- Trial name
- Unity (NCT06684847)
- Testing
- Efgartigimod PH20 SC
- Where
- 303 sites in United States, Argentina and 37 more
- Volunteers
- 631 people
- Sponsor
- argenx
Primary Sjögren's Syndrome
UCB Proof of Concept Study in Patients With Primary Sjögren's Syndrome
This is a Phase 2, multicenter, double-blind, placebo-controlled, 12-week proof-of-concept study to assess the efficacy, safety, and tolerability of UCB5857 in subjects with primary Sjögren's Syndrome (pSS).
- Trial name
- NCT02610543
- Testing
- UCB5857
- Where
- 14 sites in France, Italy and 3 more
- Volunteers
- 27 people
- Sponsor
- UCB Celltech
Primary Sjögren's Syndrome
Open-Label Extension Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren's Syndrome
Efgartigimod has the potential to improve disease manifestations by the reduction of IgG autoantibodies in Sjogren's Syndrome (SjD or pSS).
- Trial name
- Rho plus (NCT06203457)
- Testing
- Efgartigimod
- Where
- 11 sites in Belgium, Hungary and 1 more
- Volunteers
- 24 people
- Sponsor
- argenx
Systemic Lupus Erythematosus, Sjögren's Disease
A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
The purpose of this study is to evaluate the safety and tolerability of BMS-986553, CD19 in vivo Chimeric Antigen Receptor (CAR) T cells, in participants with refractory autoimmune diseases including systemic lupus erythematosus…
- Conditions
- Systemic Lupus Erythematosus, Sjögren's Disease, Rheumatoid Arthritis, Idiopathic Inflammatory Myopathies
- Trial name
- NCT07873931
- Testing
- BMS-986553
- Where
- 23 sites in United States, Belgium and 4 more
- Volunteers
- 60 people
- Sponsor
- Bristol-Myers Squibb
Primary Sjögren's Syndrome
Safety and Tolerability of IBI355 in Patients With Primary Sjogren's Syndrome
This study aims to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of IBI355 in primary Sjogren's syndrome (pSS) patients.
- Trial name
- NCT06484855
- Testing
- IBI355
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Healthy Participants, Primary Sjögren's Syndrome
BMS-986325 in Healthy Participants and Participants With Primary Sjögren's Syndrome
The purpose of this study is to evaluate the safety, tolerability, drug levels, and drug effects of BMS-986325 in healthy participants and participants with primary Sjögren's syndrome.
- Trial name
- NCT04684654
- Testing
- BMS-986325
- Where
- 2 sites in United States, Germany
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Primary Sjögren's Syndrome
PD of VAY736 in Patients With Primary Sjögren's Syndrome
This study was designed to evaluate the safety, tolerability, pharmacokinetics and therapeutic efficacy of a single intravenous infusion of VAY7346 monoclonal antibody in pSS patients
- Trial name
- CVAY736X2201 (NCT02149420)
- Testing
- VAY736
- Where
- Germany
- Volunteers
- 27 people
- Sponsor
- Novartis Pharmaceuticals
Primary Sjögren's Syndrome
A Study of INCB050465 in Primary Sjögren's Syndrome
The purpose of this study is to assess the impact of parsaclisib on the signs and symptoms of Sjögren's syndrome (SS).
- Trial name
- NCT03627065
- Testing
- Parsaclisib
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- Incyte Corporation
Dry Eye Due to Sjögren's Syndrome
Evaluate the Efficacy and Safety of LO2A Eye Drops for Symptomatic Improvement of Dry Eye in Patients With Sjögren's Syndrome
Dry eye complaints occur in 5.5 to 33.7% of the population, and are ranked as the most frequent symptoms of patients visiting ophthalmologists.
- Trial name
- NCT03319420
- Testing
- LO2A eye drops, Systane Ultra UD
- Where
- 5 sites in Israel
- Volunteers
- 60 people
- Sponsor
- Ocuwize LTD
Sjögren´s Disease
Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden
The purpose of this study is to demonstrate the efficacy and safety of ianalumab (VAY736) 300 mg administered subcutaneously (s.c.) monthly for 52 weeks in adult participants with Sjögren's disease who have high symptom burden.
- Trial name
- THALASSA (NCT07621809)
- Testing
- VAY736
- Where
- 33 sites in United States, Australia and 6 more
- Volunteers
- 570 people
- Sponsor
- Novartis Pharmaceuticals
Sjogrens Syndrome
A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.
The purpose of this study is to measure the long-term safety and tolerability of ianalumab in participants with Sjögren's syndrome who have previously completed treatment from one of two NEPTUNUS 1 year core studies (CVAY736A2301…
- Trial name
- NEPTUNUS-Ext (NCT05985915)
- Testing
- Ianalumab (VAY736)
- Where
- 198 sites in United States, Argentina and 33 more
- Volunteers
- 612 people
- Sponsor
- Novartis Pharmaceuticals
Sjögren's Syndrome (SS)
A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State
Primary Objective: To evaluate the effect of dazodalibep on patient-reported symptoms of SS in participants with moderate-to-severe symptom state Secondary Objectives: 1.
- Trial name
- NCT06245408
- Testing
- Dazodalibep
- Where
- 194 sites in United States, Argentina and 24 more
- Volunteers
- 434 people
- Sponsor
- Amgen
Xerostomia, Sjogren's Syndrome
Exploratory Study for Dry Mouth in Patients With Sjögren's Syndrome
The purpose of this study is to exploratively investigate the clinical efficacy of rebamipide on dry mouth in patients with Sjögren's syndrome in comparison with placebo.
- Trial name
- NCT00233363
- Testing
- Rebamipide
- Where
- Japan
- Volunteers
- 104 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.